Aa
Inteferon Lamda
Peginterferon Lambda, a New Potential Therapeutic Option for the Treatment of Chronic Hepatitis B: A Phase 2B Comparison with Peginterferon Alfa in Patients with HBeAg-Positive Disease
Link : http://hepatitiscnewdrugs.blogspot.com/
Link : http://hepatitiscnewdrugs.blogspot.com/
Peginterferon Lambda, a New Potential Therapeutic Option for the Treatment of Chronic Hepatitis B.
A Phase 2B Comparison with Peginterferon Alfa in Patients with HBeAg-Positive .
Conclusion : Lamda is better at reducing & clearing HBsag compared to Alfa.
Link : http://archive.mail-list.com/hbv_research/message/20121113.234908.428760a2.en.html
A Phase 2B Comparison with Peginterferon Alfa in Patients with HBeAg-Positive .
Conclusion : Lamda is better at reducing & clearing HBsag compared to Alfa.
Link : http://archive.mail-list.com/hbv_research/message/20121113.234908.428760a2.en.html
makes me really sick to read these articles. They run it as a business like a product development.. and you wonder why there is no cure for HBV still? This is called profiteering on death. "treatment market is so lucrative" - who are these clowns to use these kind of vocabulary in such a disaster situation that we have to live.
These viruses HBV, HIV, and HCV require global public funding investment.. Meaning governments, public donations - not big Pharma that trades on NASDAQ should be in control of this. Otherwise it is eugenics for profit, they don't release or develop drugs that could be cures because of a responsibility to investors.
These people are evil if they only care about this.
"Credit Suisse Group AG in New York, said she sent a note to clients projecting that Gilead would have $3.8 billion in hepatitis C sales in 2020, and Abbott would follow with $2.5 billion"
Ahhh I am lost for words..
p.s. Good new on the Lambda interferon.. but we need it NOW. What are they doing to make it available for people today? That is what I am more interested in..
=====================================================
Investment Commentary
Abbott's hepatitis C trial announcement evidently sent shivers down the spines of Gilead Science (NASDAQ: GILD) shareholders. Traders must have feared that Gilead ran the risk of being overtaken in the race for supremacy in the worldwide market for new hepatitis C treatments. After all, the stakes are high, with the market expected to reach $20 billion by 2020, according to Bloomberg.
Order seems to have been restored, though. Gilead appears to be back in favor. Evidently investors are confident that Gilead's two-drug regimen is going to prove superior to Abbott's and other competitors when all is said and done. One big drawback of the Abbott regimen is that it contains the drug ritonavir, which physicians don't want to use.
That's far from saying Gilead will have the market all to itself. According to an article in Bloomberg, Catherine Arnold, an analyst with Credit Suisse Group AG in New York, said she sent a note to clients projecting that Gilead would have $3.8 billion in hepatitis C sales in 2020, and Abbott would follow with $2.5 billion.
Another major player is expected to be Bristol-Myers Squibb (NYSE: BMY), with $1.3 billion. The company reported this week that one of its drug combinations helped patients who hadn't previously been treated for the viral infection.
Given that the hepatitis C treatment market is so lucrative, it's attracted others than the Big Three already mentioned. Companies testing therapies, either alone or together, include Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Merck (NYSE: MRK) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX).
For now, Gilead is still King of the Hill. The company has an 800-patient trial underway, and it's possible results of that study could be reported at the American Association for the Study of Liver Diseases' annual meeting next month in Boston. If that happens, we might see Gilead apply for FDA approval as soon as the middle of 2014.
Given the uncertainties in the Hep-C Market Stock Traders Daily has produced detailed trading reports for the Stocks Mentioned in this article.
Riding high after hitting a 52-week high on Monday, Abbott Laboratories (NYSE: ABT) has taken a punch to the gut as investors haven't liked what they've heard about taxes. Specifically, the tax rate that's going to be paid by the two companies Abbott will split into later this year. The new rate is expected to be about 10% higher than the company's been paying, and that boost is expected to dampen earnings at both firms.
These viruses HBV, HIV, and HCV require global public funding investment.. Meaning governments, public donations - not big Pharma that trades on NASDAQ should be in control of this. Otherwise it is eugenics for profit, they don't release or develop drugs that could be cures because of a responsibility to investors.
These people are evil if they only care about this.
"Credit Suisse Group AG in New York, said she sent a note to clients projecting that Gilead would have $3.8 billion in hepatitis C sales in 2020, and Abbott would follow with $2.5 billion"
Ahhh I am lost for words..
p.s. Good new on the Lambda interferon.. but we need it NOW. What are they doing to make it available for people today? That is what I am more interested in..
=====================================================
Investment Commentary
Abbott's hepatitis C trial announcement evidently sent shivers down the spines of Gilead Science (NASDAQ: GILD) shareholders. Traders must have feared that Gilead ran the risk of being overtaken in the race for supremacy in the worldwide market for new hepatitis C treatments. After all, the stakes are high, with the market expected to reach $20 billion by 2020, according to Bloomberg.
Order seems to have been restored, though. Gilead appears to be back in favor. Evidently investors are confident that Gilead's two-drug regimen is going to prove superior to Abbott's and other competitors when all is said and done. One big drawback of the Abbott regimen is that it contains the drug ritonavir, which physicians don't want to use.
That's far from saying Gilead will have the market all to itself. According to an article in Bloomberg, Catherine Arnold, an analyst with Credit Suisse Group AG in New York, said she sent a note to clients projecting that Gilead would have $3.8 billion in hepatitis C sales in 2020, and Abbott would follow with $2.5 billion.
Another major player is expected to be Bristol-Myers Squibb (NYSE: BMY), with $1.3 billion. The company reported this week that one of its drug combinations helped patients who hadn't previously been treated for the viral infection.
Given that the hepatitis C treatment market is so lucrative, it's attracted others than the Big Three already mentioned. Companies testing therapies, either alone or together, include Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Merck (NYSE: MRK) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX).
For now, Gilead is still King of the Hill. The company has an 800-patient trial underway, and it's possible results of that study could be reported at the American Association for the Study of Liver Diseases' annual meeting next month in Boston. If that happens, we might see Gilead apply for FDA approval as soon as the middle of 2014.
Given the uncertainties in the Hep-C Market Stock Traders Daily has produced detailed trading reports for the Stocks Mentioned in this article.
Riding high after hitting a 52-week high on Monday, Abbott Laboratories (NYSE: ABT) has taken a punch to the gut as investors haven't liked what they've heard about taxes. Specifically, the tax rate that's going to be paid by the two companies Abbott will split into later this year. The new rate is expected to be about 10% higher than the company's been paying, and that boost is expected to dampen earnings at both firms.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
